Study of heart medication and amyloid levels over time
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This study looks at how a heart medication (tafamidis) affects amyloid protein levels in the blood over time. It may help doctors understand how well the treatment works for people with a specific type of heart disease caused by amyloid buildup (ATTR-CM).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 30 and 80 years old.
- You have been diagnosed with heart failure, for example, you were hospitalized for it in the last year or have certain high blood test results.
- You have a confirmed diagnosis of ATTR-CM by biopsy or other standard tests.
- You have had genetic testing for TTR gene changes (results available or pending).
- You are either about to start a TTR-stabilizing medication (like tafamidis) or you are already taking it.
- You do not have a history of light-chain amyloidosis, heart or liver transplant, or severe kidney disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows patients with a specific type of heart amyloidosis (wild-type ATTR) who are taking or could start the drug tafamidis. It aims to learn more about how the condition and treatment affect people over time.
This study looks at people who carry certain TTR gene variants, which can cause a specific type of heart amyloid buildup. It also includes people with symptoms, to understand how the condition develops and how it may be monitored.
This study uses heart imaging to track disease progression in people with ATTR cardiac amyloidosis who are about to start tafamidis treatment. It aims to understand how the disease changes over time.
This study uses special imaging tracers to see how much they build up in the heart in people with cardiac transthyretin (ATTR) amyloidosis. It may help researchers better measure disease activity and understand who benefits from treatments like tafamidis.
This study tests a new treatment, NTLA-2001, for people with a type of heart disease called transthyretin amyloidosis with cardiomyopathy. It aims to see if the medicine can help improve heart function and quality of life.
This study tests a new medication called coramitug to see if it can reduce abnormal protein deposits in the heart. You will have special PET/CT scans to measure how the drug affects these deposits.
Hear when a new Transthyretin (TTR) Amyloid Cardiomyopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.